Previous post Next post

Novartis and Microsoft to develop drugs using AI

Joint research activities will be carried out at the Novartis Campus in Basel, Switzerland, at the Novartis Global Service Center in Dublin, Ireland, and at Microsoft Research Lab in Cambridge, Britain. (© Keystone / Georgios Kefalas)

Swiss pharmaceutical firm Novartis and computer giant Microsoft have signed a five-year partnership deal aimed at transforming the Basel-based pharma’s business – from finance to manufacturing – using artificial intelligence.

The new Novartis AI innovation lab, with Microsoft as its strategic AI and data-science partner, aims to “significantly bolster Novartis AI capabilities from research through commercialization and help accelerate the discovery and development of transformative medicines for patients worldwide”, the two firms said in a statement on Tuesdayexternal link.

Joint research activities will be carried out at the Novartis Campus in Basel, Switzerland, at the Novartis Global Service Center in Dublin, Ireland, and at the Microsoft Research Lab in Cambridge, Britain.

They hope to start focusing on personalized therapies for macular degeneration, cell & gene therapies and drug design.

Novartis Chief Executive Officer Vas Narasimhan said, “As Novartis continues evolving into a focused medicines company powered by advanced therapy platforms and data science, alliances like this will help us deliver on our purpose to reimagine medicine to improve and extend lives. Pairing our deep knowledge of human biology and medicine with Microsoft’s leading expertise in AI could transform the way we discover and develop medicines for the world.”

Full story here
About Swissinfo
Swissinfo
SWI swissinfo.ch – the international service of the Swiss Broadcasting Corporation (SBC). Since 1999, swissinfo.ch has fulfilled the federal government’s mandate to distribute information about Switzerland internationally, supplementing the online offerings of the radio and television stations of the SBC. Today, the international service is directed above all at an international audience interested in Switzerland, as well as at Swiss citizens living abroad.
Previous post See more for 3.) Swiss Info Next post
Tags: ,,

Permanent link to this article: https://snbchf.com/2019/10/novartis-microsoft-develop-drugs-ai/

Leave a Reply

Your email address will not be published.

You may use these HTML tags and attributes: <a href="" title=""> <abbr title=""> <acronym title=""> <b> <blockquote cite=""> <cite> <code> <del datetime=""> <em> <i> <q cite=""> <s> <strike> <strong>

This site uses Akismet to reduce spam. Learn how your comment data is processed.